Introduction {#H1-1-ZLD200034}
============

A secondary analysis of the Trial Assigning Individualized Options for Treatment (TAILORx) randomized clinical trial^[@zld200034r1]^ demonstrated favorable distant metastasis--free survival among patients who received adjuvant chemoendocrine therapy for hormone receptor--positive, *ERBR2*-negative, axillary node--negative breast cancer and had 21-gene recurrence scores (RSs) of 26 and higher. However, 43% of patients had RSs between 26 and 30,^[@zld200034r1]^ and the chemotherapy benefit in this subgroup remains unclear. The omission of chemotherapy has not been analyzed prospectively in such a subgroup, and current treatment guidelines recommend the consideration of chemotherapy at the discretion of the clinician.^[@zld200034r1],[@zld200034r2]^ Furthermore, although distant metastasis--free survival was previously shown to be worse among individuals with RSs of 31 or greater compared with those with RSs between 26 and 30, distant metastasis--free survival has not been validated in this patient cohort as a surrogate measure for overall survival (OS).^[@zld200034r1]^ To address this knowledge gap, we conducted a retrospective cohort study using a nationwide hospital-based cancer registry to investigate the association of OS with receiving chemotherapy and having an RS of 26 to 30 compared with having an RS of 31 or greater.

Methods {#H1-2-ZLD200034}
=======

Given that this study used a deidentified National Cancer Database (NCDB) database, institutional review board approval and patient consent were waived by the Roswell Park Comprehensive Cancer Center. Our report followed the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](http://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline.

The NCDB was queried for women patients diagnosed between 2010 and 2015 with hormone receptor--positive, *ERBR*-negative, axillary node--negative, T1-2N0 early-stage breast cancer with an RS of at least 26. We used the Kaplan-Meier method, log-rank test, and Cox multivariable analysis for OS analysis (eAppendix in the [Supplement](#note-ZLD200034-1-s){ref-type="supplementary-material"}). Propensity score matching was performed using the nearest neighbor method in a 1:1 ratio without a replacement. The standardized difference of all variables was lower than 0.1, suggestive of adequate match.^[@zld200034r3]^ Analyses were performed with R version 3.6.1 (R Project for Statistical Computing). Statistical significance was set at *P* \< .05, and all tests were 2-tailed.

Results {#H1-3-ZLD200034}
=======

A total of 17 197 patients with a median (interquartile range) age of 60 (52-67) years met our inclusion criteria. Of those, 12 741 patients (74.1%) received chemotherapy (4889 \[38.4%\] with RS 26-30; 7852 \[61.6%\] with RS ≥31) and 4456 patients (25.9%) did not receive chemotherapy (2993 \[67.2%\] with RS 26-30; 1463 \[32.8%\] with RS ≥31). The median (interquartile range) follow-up was 40.7 (23.4-60.8) months. On multivariable analysis adjusted for age, race, comorbidity burden, year of diagnosis, tumor size, surgery, and radiation, the addition of chemotherapy was associated with improved OS for all patients (hazard ratio \[HR\], 0.58; 95% CI, 0.50-0.67; *P* \< .001), and regardless of receipt of chemotherapy, having an RS of 31 or greater was associated with worse mortality (HR, 1.75; 95% CI, 1.51-2.03; *P* \< .001). Similar findings, favoring patients who received chemotherapy, were seen in 2081 matched pairs of patients with RSs of 26 to 30 who did and did not receive chemotherapy (HR, 0.70; 95% CI, 0.51-0.98; *P* = .04) ([Figure](#zld200034f1){ref-type="fig"} and [Table](#zld200034t1){ref-type="table"}). Likewise, in 3278 matched pairs of patients who received chemotherapy and had RSs of 26 to 30 or of 31 or greater, having an RS of 31 or greater was associated with worse mortality (HR, 1.85; 95% CI, 1.42-2.40; *P* \< .001) ([Figure](#zld200034f1){ref-type="fig"} and [Table](#zld200034t1){ref-type="table"}). On interaction analysis, the magnitude of the chemotherapy benefit was comparable between patients with RSs of 26 to 30 (HR, 0.59; 95% CI, 0.46-0.76; *P* \< .001) and RSs of 31 or greater (HR, 0.56; 95% CI, 0.46-0.68; *P* \< .001; *P*for interaction = .70).
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###### Baseline Characteristics for Matched Cohorts

  Characteristic                                      Patients with RS 26-30, No. (%)   *P* value          Patients who received chemotherapy, No. (%)   *P* value                             
  --------------------------------------------------- --------------------------------- ------------------ --------------------------------------------- ------------------ ------------------ -------
  Facility volume                                                                                                                                                                              
  Low                                                 122 (5.9)                         109 (5.2)          .42                                           129 (3.9)          125 (3.8)          .44
  Intermediate                                        402 (19.3)                        430 (20.7)         593 (18.1)                                    555 (16.9)                            
  High                                                1557 (74.8)                       1542 (74.1)        2556 (78.0)                                   2598 (79.3)                           
  Age, y                                                                                                                                                                                       
  \<65                                                1356 (65.2)                       1375 (66.1)        .56                                           2612 (79.7)        2610 (79.6)        .98
  ≥65                                                 725 (34.8)                        706 (33.9)         666 (20.3)                                    668 (20.4)                            
  CDS                                                                                                                                                                                          
  0                                                   1825 (87.7)                       1780 (85.5)        .12                                           2967 (90.5)        2954 (90.1)        .86
  1                                                   215 (10.3)                        250 (12.0)         284 (8.7)                                     295 (9.0)                             
  ≥2                                                  41 (2.0)                          51 (2.5)           27 (0.8)                                      29 (0.9)                              
  Education                                                                                                                                                                                    
  More educated                                       1447 (69.5)                       1388 (66.7)        .13                                           2311 (70.5)        2261 (69.0)        .19
  Less educated                                       631 (30.3)                        689 (33.1)         967 (29.5)                                    1017 (31.0)                           
  Not available                                       3 (0.1)                           4 (0.2)            0                                             0                                     
  Histology                                                                                                                                                                                    
  Ductal or lobular                                   2080 (99.9)                       2081 (100)         \>.99                                         3278 (100)         3277 (99.9)        \>.99
  Others                                              1 (0.1)                           0                  0                                             1 (0.1)                               
  Grade                                                                                                                                                                                        
  Well differentiated                                 258 (12.4)                        254 (12.2)         .06                                           158 (4.8)          155 (4.7)          .98
  Moderately differentiated                           1119 (53.8)                       1205 (57.9)        1508 (46)                                     1521 (46.4)                           
  Poorly differentiated                               623 (29.9)                        543 (26.1)         1531 (46.7)                                   1518 (46.3)                           
  Other differentiation                               3 (0.1)                           4 (0.2)            2 (0.1)                                       1 (0.1)                               
  Not available                                       78 (3.7)                          75 (3.6)           79 (2.4)                                      83 (2.5)                              
  Race                                                                                                                                                                                         
  White                                               1820 (87.5)                       1816 (87.3)        .18                                           2936 (89.6)        2925 (89.2)        .93
  Black                                               178 (8.6)                         157 (7.5)          222 (6.8)                                     229 (7.0)                             
  Other                                               69 (3.3)                          93 (4.5)           107 (3.3)                                     113 (3.4)                             
  Not available                                       14 (0.7)                          15 (0.7)           13 (0.4)                                      11 (0.3)                              
  Year                                                                                                                                                                                         
  2010-2012                                           845 (40.6)                        836 (40.2)         .80                                           1385 (42.3)        1396 (42.6)        .80
  2013-2015                                           1236 (59.4)                       1245 (59.8)        1893 (57.7)                                   1882 (57.4)                           
  Pathologic T stage                                                                                                                                                                           
  1                                                   1627 (78.2)                       1573 (75.6)        .05                                           2370 (72.3)        2414 (73.6)        .23
  2                                                   454 (21.8)                        508 (24.4)         908 (27.7)                                    864 (26.4)                            
  Lymph nodes examined                                                                                                                                                                         
  ≤2                                                  1105 (53.1)                       1103 (53.0)        .54                                           1657 (50.5)        1692 (51.6)        .36
  \>2                                                 968 (46.5)                        974 (46.8)         1616 (49.3)                                   1584 (48.3)                           
  Not available                                       8 (0.4)                           4 (0.2)            5 (0.2)                                       2 (0.1)                               
  Hormone receptor                                                                                                                                                                             
  ER+/PR+                                             1645 (79.0)                       1676 (80.5)        .31                                           2607 (79.5)        2600 (79.3)        .91
  ER+/PR-                                             433 (20.8)                        404 (19.4)         669 (20.4)                                    675 (20.6)                            
  ER−/PR+                                             3 (0.1)                           1 (0.1)            2 (0.1)                                       3 (0.1)                               
  Surgery                                                                                                                                                                                      
  Lumpectomy                                          1493 (71.7)                       1498 (72.0)        .89                                           2189 (66.8)        2189 (66.8)        \>.99
  Mastectomy                                          588 (28.3)                        583 (28.0)         1088 (33.2)                                   1088 (33.2)                           
  Other                                               0                                 0                  1 (0.1)                                       1 (0.1)                               
  Margin                                                                                                                                                                                       
  Negative                                            2028 (97.5)                       2015 (96.8)        .48                                           3236 (98.7)        3246 (99.0)        .43
  Positive                                            49 (2.4)                          62 (3)             38 (1.2)                                      30 (0.9)                              
  Not available                                       4 (0.2)                           4 (0.2)            4 (0.1)                                       2 (0.1)                               
  Radiation                                                                                                                                                                                    
  None                                                595 (28.6)                        606 (29.1)         .87                                           1074 (32.8)        1083 (33.0)        .65
  External beam                                       1380 (66.3)                       1375 (66.1)        2112 (64.4)                                   2115 (64.5)                           
  Others                                              106 (5.1)                         100 (4.8)          92 (2.8)                                      80 (2.4)                              
  Total                                                                                                                                                                                        
  Radiation dose, median (IQR), Gy                    60 (52.4-61.2)                    60.4 (52.6-62.0)   .08                                           60.4 (52.7-61.2)   60.4 (52.7-61.0)   .60
  Readmission within 30 d                                                                                                                                                                      
  None                                                1983 (95.3)                       1973 (94.8)        .23                                           3105 (94.7)        3074 (93.8)        .09
  Unplanned                                           30 (1.4)                          20 (1.0)           42 (1.3)                                      45 (1.4)                              
  Planned                                             35 (1.7)                          51 (2.5)           68 (2.1)                                      103 (3.1)                             
  Others                                              3 (0.1)                           5 (0.2)            5 (0.2)                                       4 (0.1)                               
  Not available                                       30 (1.4)                          32 (1.5)           58 (1.8)                                      52 (1.6)                              
  Postoperative inpatient duration, median (IQR), d   0 (0-1)                           0 (0-1)            .44                                           0 (0-1)            0 (0-1)            .18

Abbreviations: CDS, Charlson-Deyo Comorbidity Score; ER, estrogen receptor; IQR, interquartile range; PR, progesterone receptor; RS, 21-gene recurrence score.

Discussion {#H1-4-ZLD200034}
==========

The magnitude of adjuvant chemotherapy benefit among patients with high risk (ie, RS ≥31) has previously been described.^[@zld200034r4]^ To our knowledge, this is the first study to report the association of adjuvant chemotherapy with improved OS in patients with breast cancer, with comparable magnitude between those with RSs of 26 to 30 and those with RSs of 31 or greater. Having an RS of 31 or greater remained independently associated with worse mortality compared with having an RS of 26 to 30 despite receiving chemotherapy, consistent with the secondary analysis of TAILORx.^[@zld200034r1]^ Pertinent variables, such as performance status, were unavailable in the NCDB, and lack of adjustment during matching could result in residual selection bias. In the propensity score matching analysis, postoperative readmissions and duration of postoperative inpatient admission were matched as proxy measures for postoperative complications and performance status prior to receiving adjuvant therapies.^[@zld200034r5]^ While we await further prospective studies, the data presented here may inform clinicians' decisions for systemic therapy in patients with RSs of 26 to 30.
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